Describing Patient With DME, Their Patient Journey and Disease Progression

Completed

• Conditions: Diabetic Macular Edema

• Registration Number: NCT05966753
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

This study aims to characterize patients with diabetic macular edema (DME), their progression, the treatment received and associate the functional and physiological outcomes related to the treatment.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-07-21
• Study First Submitted QC: 2023-07-21
• Study First Posted: 2023-08-01
• Study Start: 2023-08-03
• Primary Completion: 2023-12-31
• Study Completion: 2023-12-31
• Status Verified: 2024-12
• Last Update Submitted: 2024-12-17
• Last Update Posted: 2024-12-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 221004

Inclusion Criteria

All patients ≥18 years, with a DME diagnosis in at least one eye, included in the Vestrum database identified during the study period (January 2015 to April 2023)

Exclusion Criteria

Patients without the information of laterality will be excluded.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in visual acuity	From January 2015 to April 2023
Progression to DME in the fellow eye	From January 2015 to April 2023
Central retinal thickness (CRT)	From January 2015 to April 2023
Initial treatment of DME	From January 2015 to April 2023

Trial Locations

Locations (1)

CorEvitas HQ; 🇺🇸 Waltham, Massachusetts, United States